Reported Sunday, Novo Presents Two REDEFINE 1 Post Hoc Analyses Of CagriSema At ObesityWeek: 25.4% Mean Weight Loss In Early Responders, 73.1% Versus 49.1% Placebo Meaningful Physical Function Improvement
Benzinga Newsdesk 17 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
In a post hoc analysis of the phase 3 REDEFINE 1 trial, 67.8% of adults treated with investigational CagriSema 2.4 mg / 2.4 mg were early responders, achieving at least 5% weight loss by week 81Women were more likely to
- In a post hoc analysis of the phase 3 REDEFINE 1 trial, 67.8% of adults treated with investigational CagriSema 2.4 mg / 2.4 mg were early responders, achieving at least 5% weight loss by week 81
- Women were more likely to be early responders than delayed responders (71.8% vs 59.5%)1
- In a separate post hoc analysis of REDEFINE 1, significantly more adults with overweight or obesity treated with investigational CagriSema 2.4 mg / 2.4 mg reported a meaningful improvement in physical function at 68 weeks compared with placebo (73.1% vs 49.1%; efficacy estimand*)2
